SAB Biotherapeutics, Inc. (SABSW) News
Follow SAB Biotherapeutics, Inc. (SABSW) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 6 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
SAB BIO Reports Q3 2026 Financial Results and Business Highlights
Adult and adolescent cohorts are fully enrolled in the registrational SAFEGUARD study of SAB-142.
EQUITY | Nov 05, 2026, 12:30 PM UTC
L
SAB Biotherapeutics Receives FDA Fast Track Designation for SAB-142
The FDA granted Fast Track designation to SAB-142 for Stage 3 type 1 diabetes.
REGULATION | Oct 13, 2026, 12:30 PM UTC
L
SABS SABSW - SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes
SABS SABSW - SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes
NEWS | Sep 22, 2026, 12:30 PM UTC
L
SABS SABSW - SAB BIO to Participate in Upcoming Investor Conferences
SABS SABSW - SAB BIO to Participate in Upcoming Investor Conferences
EQUITY | Sep 01, 2026, 12:30 PM UTC
L
SABS SABSW - SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights
SABS SABSW - SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights
EARNINGS | Aug 06, 2026, 11:30 AM UTC
L
SABS SABSW - SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET - Click For Re
SABS SABSW - SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET
EARNINGS | Jul 30, 2026, 12:30 PM UTC